Nature Medicine最新文献

{"title":"Anti-amyloid could help prevent genetic form of Alzheimer’s disease","authors":"","doi":"10.1038/d41591-025-00026-8","DOIUrl":"https://doi.org/10.1038/d41591-025-00026-8","url":null,"abstract":"Despite a negative primary outcome, a trial of gantenerumab showed a clinically meaningful slowing of disease onset in asymptomatic people who were treated for the longest duration.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"58 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143842005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BCMA-CAR T-cells in a patient with relapsing idiopathic inflammatory myositis after CD19-CAR T-cells","authors":"Fabian Müller, Andreas Wirsching, Melanie Hagen, Simon Völkl, Carlo Tur, Maria Gabriella Raimondo, Jule Taubmann, Laura Bucci, Liang Zhang, Sascha Kretschmann, Michael Aigner, Markus Eckstein, Silvia Spörl, Soraya Kharboutli, Sebastian Böltz, Armin Atzinger, Luis Munoz, Georg Schett, Andreas Mackensen, Ricardo Grieshaber-Bouyer","doi":"10.1038/s41591-025-03718-3","DOIUrl":"https://doi.org/10.1038/s41591-025-03718-3","url":null,"abstract":"<p>CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy has been shown to induce stable drug-free remission in patients with refractory autoimmune disease. The management of potential relapses is currently unclear. Here, we report on a 45-year-old woman with treatment-refractory Jo-1-associated anti-synthetase syndrome, who initially achieved disease remission after CD19-CAR T-cell therapy but then experienced disease relapse after 9 months. After reinfusion of the same product, CAR T-cells failed to expand and anti-CD19-CAR T-cells were detected. Despite full-dose lymphodepletion, no clinical response was observed. After bridging with anti-CD38 antibody daratumumab, which was efficacious with limited durability, plasma cell-targeting BCMA-CAR T-cell therapy was performed. BCMA-CAR T-cells expanded, cleared plasma cells in lymphoid tissue, reduced autoantibody levels, and re-induced stable drug-free remission. This case highlights the challenges in CAR T-cell reinfusion, the potential of alternative targets and products and suggests that the depletion of plasma cells may enhance therapeutic outcomes in patients who become treatment-refractory.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"37 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using AI to screen for opioid use disorder","authors":"Louisa Picco, Suzanne Nielsen","doi":"10.1038/s41591-025-03673-z","DOIUrl":"https://doi.org/10.1038/s41591-025-03673-z","url":null,"abstract":"An AI-driven screener for opioid use disorder in hospital settings could increase referrals to addiction services and improve patient outcomes, but it is crucial that treatment is accessible and that unintended harms such as stigma are avoided.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"6 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143842004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author Correction: Mpox poses an ever-increasing epidemic and pandemic risk","authors":"Carlos Maluquer de Motes, David O. Ulaeto","doi":"10.1038/s41591-025-03707-6","DOIUrl":"https://doi.org/10.1038/s41591-025-03707-6","url":null,"abstract":"<p>Correction to: <i>Nature Medicine</i> https://doi.org/10.1038/s41591-025-03589-8, published online 1 April 2025.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"20 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143842025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","authors":"Lindsay B. Kilburn, Dong-Anh Khuong-Quang, Jordan R. Hansford, Daniel Landi, Jasper van der Lugt, Sarah E. S. Leary, Pablo Hernáiz Driever, Simon Bailey, Sébastien Perreault, Geoffrey McCowage, Angela J. Waanders, David S. Ziegler, Olaf Witt, Patricia A. Baxter, Hyoung Jin Kang, Timothy E. Hassall, Jung Woo Han, Darren Hargrave, Andrea T. Franson, Michal Yalon Oren, Helen Toledano, Valérie Larouche, Cassie Kline, Mohamed S. Abdelbaki, Nada Jabado, Nicholas G. Gottardo, Nicolas U. Gerber, Nicholas S. Whipple, Devorah Segal, Susan N. Chi, Liat Oren, Enrica E. K. Tan, Sabine Mueller, Izzy Cornelio, Lisa McLeod, Xin Zhao, Ashley Walter, Daniel Da Costa, Peter Manley, Samuel C. Blackman, Roger J. Packer, Karsten Nysom","doi":"10.1038/s41591-025-03709-4","DOIUrl":"https://doi.org/10.1038/s41591-025-03709-4","url":null,"abstract":"<p>Correction to: <i>Nature Medicine</i> https://doi.org/10.1038/s41591-023-02668-y, published online 17 November 2023.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"35 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143837286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-prediction of coronary artery disease risk","authors":"Shang-Fu Chen, Sang Eun Lee, Hossein Javedani Sadaei, Jun-Bean Park, Ahmed Khattab, Jei-Fu Chen, Corneliu Henegar, Nathan E. Wineinger, Evan D. Muse, Ali Torkamani","doi":"10.1038/s41591-025-03648-0","DOIUrl":"https://doi.org/10.1038/s41591-025-03648-0","url":null,"abstract":"<p>Coronary artery disease (CAD) is a leading cause of morbidity and mortality worldwide, and accurately predicting individual risk is critical for prevention. Here we aimed to integrate unmodifiable risk factors, such as age and genetics, with modifiable risk factors, such as clinical and biometric measurements, into a meta-prediction framework that produces actionable and personalized risk estimates. In the initial development of the model, ~2,000 predictive features were considered, including demographic data, lifestyle factors, physical measurements, laboratory tests, medication usage, diagnoses and genetics. To power our meta-prediction approach, we stratified the UK Biobank into two primary cohorts: first, a prevalent CAD cohort used to train predictive models for cross-sectional prediction at baseline and prospective estimation of contributing risk factor levels and diagnoses (baseline models) and, second, an incident CAD cohort using, in part, these baseline models as meta-features to train a final CAD incident risk prediction model. The resultant 10-year incident CAD risk model, composed of 15 derived meta-features with multiple embedded polygenic risk scores, achieves an area under the curve of 0.84. In an independent test cohort from the All of Us research program, this model achieved an area under the curve of 0.81 for predicting 10-year incident CAD risk, outperforming standard clinical scores and previously developed integrative models. Moreover, this framework enables the generation of individualized risk reduction profiles by quantifying the potential impact of standard clinical interventions. Notably, genetic risk influences the extent to which these interventions reduce overall CAD risk, allowing for tailored prevention strategies.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"58 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143836902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Publisher Correction: Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial","authors":"Frank J. Lowery, Stephanie L. Goff, Billel Gasmi, Maria R. Parkhurst, Nivedita M. Ratnam, Hyunmi K. Halas, Thomas E. Shelton, Michelle M. Langhan, Aarushi Bhasin, Aaron J. Dinerman, Victoria Dulemba, Ian S. Goldlust, Alexandra M. Gustafson, Abraham A. Hakim, Kyle J. Hitscherich, Lisa M. Kenney, Lior Levy, Juliette G. Rault-Wang, Alakesh Bera, Satyajit Ray, Courtney D. Seavey, Chuong D. Hoang, Jonathan M. Hernandez, Jared J. Gartner, Sivasish Sindiri, Todd D. Prickett, Lori S. McIntyre, Sri Krishna, Paul F. Robbins, Nicholas D. Klemen, Mei Li M. Kwong, James C. Yang, Steven A. Rosenberg","doi":"10.1038/s41591-025-03708-5","DOIUrl":"https://doi.org/10.1038/s41591-025-03708-5","url":null,"abstract":"<p>Correction to: <i>Nature Medicine</i> https://doi.org/10.1038/s41591-025-03627-5, published online 1 April 2025.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"20 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143837289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can AI-powered brain–computer interfaces boost human intelligence?","authors":"","doi":"10.1038/s41591-025-03641-7","DOIUrl":"https://doi.org/10.1038/s41591-025-03641-7","url":null,"abstract":"The latest brain–computer interfaces in pre-clinical testing receive — and send — signals, training the brains of participants.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"238 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143832482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author Correction: LILRB3 genetic variation is associated with kidney transplant failure in African American recipients","authors":"Zeguo Sun, Zhengzi Yi, Chengguo Wei, Wenlin Wang, Tianyuan Ren, Paolo Cravedi, Fasika Tedla, Stephen C. Ward, Evren Azeloglu, Daniel R. Schrider, Yun Li, Atlas Khan, Francesca Zanoni, Jia Fu, Sumaria Ali, Shun Liu, Deguang Liang, Tong Liu, Hong Li, Caixia Xi, Thi Ha Vy, Gohar Mosoyan, Quan Sun, Ashwani Kumar, Zhongyang Zhang, Samira Farouk, Kirk Campell, Jordi Ochando, Kyung Lee, Steve Coca, Jenny Xiang, Patricia Connolly, Lorenzo Gallon, Philip J. O’Connell, Robert Colvin, Madhav C. Menon, Girish Nadkarni, John C. He, Monica Kraft, Xuejun Jiang, Xuewu Zhang, Krzysztof Kiryluk, Aravind Cherukuri, Fadi G. Lakkis, Weiguo Zhang, Shu-hsia Chen, Peter S. Heeger, Weijia Zhang","doi":"10.1038/s41591-025-03706-7","DOIUrl":"https://doi.org/10.1038/s41591-025-03706-7","url":null,"abstract":"<p>Correction to: <i>Nature Medicine</i> https://doi.org/10.1038/s41591-025-03568-z, published online 10 March 2025.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"6 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143837287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CONSORT 2025 statement: updated guideline for reporting randomized trials","authors":"Sally Hopewell, An-Wen Chan, Gary S. Collins, Asbjørn Hróbjartsson, David Moher, Kenneth F. Schulz, Ruth Tunn, Rakesh Aggarwal, Michael Berkwits, Jesse A. Berlin, Nita Bhandari, Nancy J. Butcher, Marion K. Campbell, Runcie C. W. Chidebe, Diana Elbourne, Andrew Farmer, Dean A. Fergusson, Robert M. Golub, Steven N. Goodman, Tammy C. Hoffmann, John P. A. Ioannidis, Brennan C. Kahan, Rachel L. Knowles, Sarah E. Lamb, Steff Lewis, Elizabeth Loder, Martin Offringa, Philippe Ravaud, Dawn P. Richards, Frank W. Rockhold, David L. Schriger, Nandi L. Siegfried, Sophie Staniszewska, Rod S. Taylor, Lehana Thabane, David Torgerson, Sunita Vohra, Ian R. White, Isabelle Boutron","doi":"10.1038/s41591-025-03635-5","DOIUrl":"https://doi.org/10.1038/s41591-025-03635-5","url":null,"abstract":"<p>Well-designed and properly executed randomized trials are considered the most reliable evidence on the benefits of healthcare interventions. However, there is overwhelming evidence that the quality of reporting is not optimal. The CONSORT (Consolidated Standards of Reporting Trials) statement was designed to improve the quality of reporting and provides a minimum set of items to be included in a report of a randomized trial. CONSORT was first published in 1996, then updated in 2001 and 2010. Here, we present the updated CONSORT 2025 statement, which aims to account for recent methodological advancements and feedback from end users. We conducted a scoping review of the literature and developed a project-specific database of empirical and theoretical evidence related to CONSORT, to generate a list of potential changes to the checklist. The list was enriched with recommendations provided by the lead authors of existing CONSORT extensions (Harms, Outcomes, Non-Pharmacological Treatment), other related reporting guidelines (TIDieR) and recommendations from other sources (such as personal communications). The list of potential changes to the checklist was assessed in a large, international, online, three-round Delphi survey involving 317 participants and discussed at a two-day online expert consensus meeting of 30 invited international experts. We have made substantive changes to the CONSORT checklist. We added seven new checklist items, revised three items, deleted one item, and integrated several items from key CONSORT extensions. We also restructured the CONSORT checklist, with a new section on open science. The CONSORT 2025 statement consists of a 30-item checklist of essential items that should be included when reporting the results of a randomized trial and a diagram for documenting the flow of participants through the trial. To facilitate implementation of CONSORT 2025, we have also developed an expanded version of the CONSORT 2025 checklist, with bullet points eliciting critical elements of each item. Authors, editors, reviewers, and other potential users should use CONSORT 2025 when writing and evaluating manuscripts of randomized trials to ensure that trial reports are clear and transparent.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"57 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}